The development of the first line treatment of metastatic colorectal cancer (mCRC);A távoli áttétes kolorektális rák (mCRC) elso választású kezelésének fejlodése

Magyar Onkologia

Volumn 53, Issue 3, 2009, Pages 237-246

  Landherr, László ^a   Nagykálnai, Tamás ^a  

^a Onkoradiológiai Központ ^*  (Hungary)

Author keywords

Colorectal cancer; First line chemotherapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; SORAFENIB; UFT; VASCULOTROPIN RECEPTOR;

BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; NEUROTOXICITY; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; INDIVIDUALIZED MEDICINE; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 70449491057     PISSN: 00250244     EISSN: None     Source Type: Journal    
DOI: 10.1556/MOnkol.53.2009.3.1     Document Type: Review

References (61)

1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
2. André T, Tabernero J, Van Cutsem, et al. Phase II study with cetuximab plus FOLFOX-4 in first-line sett ing for epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Final results. 2007 Gastrointestinal Cancers Symposium, 2007
3. Arkenau H-T, Schmoll S, Kubicka A, et al. Infusional 5-fluorouracil/ folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. Proc ASCO 23:247s, Abstr 3507, 2005
4. Berry SR, Van Cutsem E, Kretzschmar A, et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. J Clin Oncol 26(15 Suppl):4025, 2008
5. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084-2091, 2004
6. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunochemistry. J Clin Oncol 23:1803-1810, 2005
7. ClinicalTrials.gov. Cetuximab and/or bevacizumab combined with combination chemotherapy in treating patients with metastatic colorectal cancer. http://www.clinicaltrials.gov/ct/show/NCT00265850?order=1
8. Cunningham D, Sirohi B, Pluzanska A, et al. Two different firstline 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 20:244-250, 2009
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plusirinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
10. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
11. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166-1169, 2007
12. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
13. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047, 2000
14. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676, 2007
15. Folprecht G, Gruenberger T, Hartmann JT, et al. Randomized multicenter study of cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CELIM-study). ESMO 2008, Abstr 510PD
16. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139-1145, 2007
17. Fuchs CS, Marshall J, Mitchell EP, et al. Updated results of BICC-C study comparing first-line irinotecan/fl uoropyrimidine combinations with or without celecoxib in mCRC: Updated efficacy data. J Clin Oncol 25(18 Suppl):4027, 2007
18. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
19. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leukovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
20. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 20:5326-5334, 2008
21. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 10:1830-1835, 2008
22. Hecht JR, Chidiac T, Mitchell E, et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (bev) for metastatic colorectal cancer (mCRC). World Gastrointestinal Cancer Congress Meeting, 2008
23. Hecht JR, Mitchell E, Chidiac T, et al. An updated analysis of the safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized controlled trial (PACCE). 2008 Gastrointestinal Cancers Symposium, 2008
24. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol 24(18 Suppl):3536, 2006
25. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fl uoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer. Results of the TREE study. J Clin Oncol 26:3523-3529, 2008
26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plusirinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
27. Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14:22-28, 2009
28. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
29. Köhne CH, Folprecht G. On prejudice and facts and choices. Ann Oncol 17:185-187, 2006
30. Köhne CH, Van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856-4865, 2005
31. Koopman M, Antonioni NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370:135-142, 2007
32. Lakatos L, Lakatos PL. A colorectalis daganatok korszerû kezelése. LAM 15:177-186, 2005
33. Liévre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
34. Liévre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
35. Mayer RJ. Targeted therapy for advanced colorectal cancer - more is not always bett er. N Engl J Med 2009, 360:623-625, 2009
36. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
37. O'Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 13:1074-1083, 2008
38. Patt YZ, Liebmann J, Diamandidis D, et al. Capecitabine (X) plusirinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety fi ndings from a phase II trial. J Clin Oncol 22(Suppl):14S, Abstr 3602, 2004
39. Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 14:5869-5876, 2008
40. Petrioli R, Paolelli L, Marsili S, et al. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 70:345-350, 2006
41. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26(15 Suppl):LBA4011, 2008
42. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
43. Sakar B, Gumus M, Basaran M, et al. XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer. Oncology 73:298-304, 2007
44. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX- 1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 25(18 Suppl):4028, 2007
45. Sanoff H, Sargent DJ, Campbell ME, et al. N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). J Clin Oncol 25:4067, 2007
46. Sartire-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238-3245, 2007
47. Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 95:131-138, 2006
48. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370:143-152, 2007
49. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798-805, 2006
50. Thirion P, Michelis S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated metaanalysis. J Clin Oncol 22:3766-3775, 2004
51. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563- 572, 2009
52. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22:229-237, 2004
53. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stopand- go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24:394-400, 2006
54. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704, 2005
55. Van Cutsem E, Hoff PM, Haper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90:1190-1197, 2004
56. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 25(18 Suppl):4000, 2007
57. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the first line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26(15 Suppl):2, 2008
58. Velho S, Oliviera C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41:1649-1654, 2005
59. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. J Clin Oncol 24(18 Suppl):3509, 2006
60. Wong R, Cunningham D. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 26:5668-5670, 2008
61. Yaman E, Uner A, Er O, et al. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. Med Oncol 24:431-435, 2007